Posted by jrbecker76 on July 21, 2008, at 23:52:12
In reply to beta2- and beta3-adrenoceptors, posted by undopaminergic on June 24, 2008, at 22:23:38
> Activation of beta2- and beta3-adrenergic receptors greatly enhances the uptake of aromatic amino acids into the CNS across the blood-brain-barrier. Since several of these amino acids are precursors to the monoamine neurotransmitters - dopamine, noradrenaline and serotonin - the potential practical implications are obvious.
>
> In other words, systemic (ie. tablets rather than inhalers) beta2-adrenergic-agonists such as clenbuterol and salbutamol/albuterol (Ventoline) may be interesting additions to a psychopharmacological regimen. In rare cases, they may even be sufficient as monotherapy.a beta-3 adrenoreceptor agonist, amibegron, is currently in late-stage clinical trials for depression/anxiety. Unfortunately, I have a feeling it will be announced as discontinued soon.
JB
poster:jrbecker76
thread:836314
URL: http://www.dr-bob.org/babble/neuro/20080706/msgs/841357.html